DEFA14A: iCAD Files Proxy Supplement Addressing Shareholder Lawsuits and Providing Updated Financial Projections for RadNet Merger

iCAD, Inc. has filed a supplement to its definitive proxy statement for the upcoming special meeting, addressing shareholder litigation related to its proposed merger with RadNet, Inc. and providing additional financial projections.

Summary

• iCAD, Inc. (iCAD) filed a Definitive Proxy Statement on May 21, 2025, concerning its Agreement and Plan of Merger with RadNet, Inc. (RadNet), dated April 15, 2025.
• A special meeting of iCAD stockholders is scheduled virtually for July 14, 2025, at 9:00 a.m. Eastern Time, to vote on the Merger Proposal.
• Two lawsuits, Smith v. iCAD and Miller v. ICAD, were filed on June 18, 2025, in the Supreme Court of the State of New York, County of New York, by purported individual stockholders, naming iCAD and its Board of Directors as defendants.
• These lawsuits allege the Definitive Proxy Statement is materially incomplete and misleading, asserting claims for negligent misrepresentation, concealment, and negligence, and seek an injunction enjoining the merger, rescission if consummated, and legal fees.
• Between May 13, 2025, and July 1, 2025, 16 demand letters were sent by purported stockholders with similar allegations, including alleged breach of fiduciary duties, requesting corrective disclosures.
• iCAD believes the allegations are without merit and that no supplemental disclosures are legally required, but is providing them to avoid nuisance, cost, and distraction, and to prevent delays to the Special Meeting or merger closing.
• The supplemental disclosures include unaudited prospective financial information for CY2025E-CY2029E, projecting Revenue growth from $21,671k in CY2025E to $50,926k in CY2029E.
• Operating Income is projected to turn positive from $(5,626)k in CY2025E to $17,008k in CY2029E, and EBITDA from $(4,721)k to $17,914k over the same period.
• Unlevered Free Cash Flow is projected to turn positive from $(2,777)k in CY2025E (9 months) to $11,187k in CY2029E.
• The document clarifies Piper Sandler's financial analysis methodologies, including an estimated net cash balance of approximately $20 million for iCAD as of March 31, 2025, and diluted shares of approximately 28.6 million.
• Comparative analysis shows iCAD's implied EV/Revenue and EV/Gross Profit multiples at the merger consideration are higher than the mean/median of selected unprofitable growth medical technology public companies but lower than the mean/median of selected M&A transactions.
• A discounted cash flow analysis yielded an implied per share value range of $2.97-$4.15, compared to the Implied Per Share Merger Consideration of $3.61.
• No iCAD directors or executive officers have entered into arrangements for continued employment with RadNet post-merger, though such arrangements are possible in the future.
• The iCAD Board of Directors continues to recommend that stockholders vote FOR the proposals being considered at the Special Meeting.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company is facing significant litigation and demand letters, which are negative, management is vigorously defending its position and has provided detailed financial projections that show future growth and profitability. The supplemental disclosures are a proactive step to mitigate risks and avoid delays, and the Board continues to recommend the merger. The financial projections, if realized, are positive, but the legal challenges introduce uncertainty.

Positives

• The iCAD Board of Directors continues to recommend voting FOR the merger proposals, indicating confidence in the transaction's strategic value.
• iCAD is vigorously defending against the shareholder litigation, asserting the claims are without merit and that no additional disclosures are legally required.
• The company's decision to provide supplemental disclosures aims to proactively address shareholder concerns, avoid nuisance, cost, and distraction, and prevent potential delays to the Special Meeting or the closing of the Merger.
• The supplemental disclosures explicitly state that they will not affect the merger consideration or the timing of the Special Meeting.
• Projected financial metrics indicate significant future growth, with revenue expected to more than double from CY2025E to CY2029E, and a return to profitability and positive unlevered free cash flow by CY2027E.

Negatives

• Two lawsuits and 16 demand letters have been filed/sent by purported stockholders, alleging the Definitive Proxy Statement is materially incomplete and misleading.
• The lawsuits seek significant remedies, including injunctions to prevent the merger, rescission if the merger is consummated, and recovery of legal fees.
• iCAD cannot predict the outcome of the Merger Litigations, nor can it estimate the amount of time, expense, or potential loss required to resolve them.
• The company is incurring costs and management distraction due to the ongoing litigation, even if it considers the claims to be without merit.

Risks

• Termination of the merger agreement or inability to complete the proposed transaction on anticipated terms and timetable.
• Inability to complete the proposed transaction due to failure to obtain iCAD stockholder approval or satisfy any other closing conditions in a timely manner or at all.
• Regulatory approval for the proposed transaction being delayed, not obtained, or obtained subject to unanticipated conditions.
• Inability to recognize the anticipated benefits of the proposed transaction, which may be affected by the ability to maintain relationships with customers, patients, payers, physicians, and providers, and retain management and key employees.
• Inability to achieve the synergies contemplated by the proposed transaction, or such synergies taking longer to realize than expected.
• Costs related to the proposed transaction.
• Inability to successfully execute strategic plans following the proposed transaction.
• Inability to promptly and effectively integrate iCAD into RadNet's business.
• Risk of litigation related to the proposed transaction.
• Diversion of management's time and attention from ordinary course business operations to completion of the proposed transaction and integration matters.
• Risk of legislative, regulatory, economic, competitive, and technological changes.
• Risks relating to the value of RadNet's securities to be issued in the proposed merger.
• The effect of the announcement, pendency, or completion of the proposed transactions on the market price of the common stock of RadNet and iCAD.
• Risks specific to iCAD, including the willingness of patients to undergo mammography screening and whether ProFound AI will improve reading efficiency, specificity, sensitivity, and reduce false positives.
• Impact of supply and manufacturing constraints or difficulties on iCAD's ability to fulfill orders.
• Uncertainty of future sales levels.
• Ability to defend itself in litigation matters.
• Protection of patents and other proprietary rights.
• Product market acceptance and possible technological obsolescence of products.
• Increased competition and government regulation.
• Changes in Medicare or other reimbursement policies.
• Risks relating to existing and future debt obligations.
• Competitive factors and the effects of a decline in the economy or markets served by the Company.

Future Outlook

iCAD projects significant revenue growth from $21.67 million in CY2025E to $50.93 million in CY2029E, with operating income, EBITDA, and unlevered free cash flow expected to turn positive and grow substantially over this period. The company anticipates the merger with RadNet to proceed as planned, with the Board continuing to recommend stockholder approval despite ongoing litigation.

Management Comments

• iCAD believes that no supplemental disclosures are required under applicable law, and that the requested additional disclosures are immaterial.
• iCAD and its directors intend to vigorously defend against each Merger Litigation and any subsequently filed similar actions.
• iCAD believes that the Demand Letters are without merit, that no supplemental disclosures are required under applicable law, and that the requested additional disclosures are immaterial.
• iCAD and all defendants in the Merger Litigations deny all allegations in the Merger Litigations and the Demand Letters and believe that no additional disclosure is required in the Definitive Proxy Statement.
• However, in order to moot the disclosure claims and avoid nuisance, cost and distraction, and with the goal of precluding any effort to delay the Special Meeting or the closing of the Merger, iCAD hereby makes additional disclosures.
• iCAD and all defendants in the Merger Litigations deny that they have violated any laws or breached any duties to iCAD stockholders in connection with the Definitive Proxy Statement, and none of the Supplemental Disclosures nor any other disclosure in this Schedule 14A should be construed as an admission of the legal necessity, legal merit or materiality under applicable laws of any Supplemental Disclosures.
• This decision to make the Supplemental Disclosures will not affect the merger consideration to be paid in connection with the Merger or the timing of the Special Meeting.
• The Board continues to recommend that you vote FOR the proposals being considered at the Special Meeting.

Industry Context

The document reflects ongoing consolidation and M&A activity within the medical technology and healthcare imaging sectors, where larger entities like RadNet are acquiring specialized technology firms such as iCAD to expand their capabilities, particularly in AI-powered diagnostics. The shareholder litigation highlights a common challenge in public merger transactions, where increased scrutiny over disclosure practices and potential shareholder activism are prevalent, often leading to legal challenges and demands for additional transparency.

Comparison to Industry Standards

• iCAD's implied EV/Revenue multiples at the merger consideration (4.3x for 2024, 3.9x for 2025, 3.6x for 2026) are notably higher than the mean (3.0x, 2.4x, 2.1x) and median (3.0x, 2.3x, 2.1x) of selected unprofitable growth medical technology public companies, including AtriCure, Inc., Neuronetics, Inc., NeuroPace, Inc., OrthoPediatrics Corp., Pulmonx Corporation, Sanara MedTech Inc., SI-BONE, Inc., Sight Sciences, Inc., and Treace Medical Concepts, Inc.
• Similarly, iCAD's implied EV/Gross Profit multiples at the merger consideration (5.0x for 2024, 4.7x for 2025, 4.2x for 2026) also exceed the mean (3.9x, 3.3x, 2.9x) and median (3.7x, 3.2x, 2.9x) of the same selected unprofitable growth medical technology public companies.
• In contrast, when compared to selected M&A transactions, iCAD's implied EV/LTM Revenue (4.3x) and EV/FTM Revenue (3.9x) are below the mean (5.4x, 4.8x) and median (5.1x, 4.7x) of comparable deals, which include Paragon 28, Inc., Silk Road Medical, Inc., Cardiovascular Systems, Inc., Misonix, Inc., The Spectranetics Corporation, LDR Holding Corporation, Uroplasty, Inc., Small Bone Innovations, Inc., and AngioScore, Inc.
• Likewise, iCAD's implied EV/LTM Gross Profit (5.0x) and EV/FTM Gross Profit (4.7x) are below the mean (7.3x, 6.4x) and median (7.5x, 6.6x) of the selected M&A transactions.
• The discounted cash flow analysis for iCAD yielded an implied per share value range of $2.97-$4.15 (based on mean and median), which effectively brackets the Implied Per Share Merger Consideration of $3.61, suggesting the merger consideration falls within a reasonable valuation range based on future cash flow projections.

Legal Proceedings

• Smith v. iCAD, 653641/2025, filed on June 18, 2025, in the Supreme Court of the State of New York, County of New York, by a purported individual stockholder, naming iCAD and its Board of Directors as defendants.
• Miller v. ICAD, 653645/2025, filed on June 18, 2025, in the Supreme Court of the State of New York, County of New York, by a purported individual stockholder, naming iCAD and its Board of Directors as defendants.
• Both lawsuits generally allege that the Definitive Proxy Statement is materially incomplete and misleading by failing to disclose purportedly material information, asserting claims for negligent misrepresentation and concealment, and negligence under New York law.
• The lawsuits seek, among other things, an injunction enjoining the consummation of the merger, rescission of the merger if consummated, and costs of the action, including attorneys' fees and experts' fees and expenses.
• From May 13, 2025, through July 1, 2025, 16 demand letters were sent by purported stockholders of iCAD regarding the preliminary proxy statement and Definitive Proxy Statement, based on similar core allegations, including alleged breach of fiduciary duties, requesting corrective disclosures.
• iCAD believes that the Merger Litigations and Demand Letters are without merit and intends to vigorously defend against them, denying any violation of laws or breach of duties to stockholders.

Stakeholder Impact

• Shareholders: Face ongoing litigation challenging the adequacy of merger disclosures, requiring them to carefully review supplemental materials and vote on the merger. The litigation introduces uncertainty regarding the merger's completion and potential for delays, although the company states the supplemental disclosures will not affect timing or consideration.
• Employees: Executive officers' future employment with RadNet post-merger is uncertain, though existing arrangements with iCAD remain in effect if new agreements are not reached.
• Customers, Patients, Payers, Physicians, and Providers: Potential impact on relationships if the anticipated benefits of the merger are not realized or if integration challenges arise.
• Creditors: The company's existing and future debt obligations are noted as a risk factor, implying potential impact depending on the merger's financial outcomes and integration.

Next Steps

• The Special Meeting of iCAD stockholders will be held on July 14, 2025, to vote on the Merger Proposal.
• iCAD and its directors intend to vigorously defend against the Merger Litigations and any subsequently filed similar actions.
• RadNet may potentially enter into arrangements regarding continued employment or service with iCAD's executive officers following the Merger.

Key Dates

Recommendation

Keywords

iCAD, RadNet, Merger, SEC Filing, Proxy Statement, Shareholder Litigation, Financial Projections, Medical Technology, Healthcare M&A, Corporate Governance, Risk Management, EBITDA, Unlevered Free Cash Flow, Special Meeting, Shareholder Vote